GO:1904339 negative regulation of dopaminergic neuron differentiation: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904339 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of dopaminergic neuron differentiation.
• Negative regulation of dopaminergic neuron differentiation is essential for balancing the generation of midbrain dopaminergic neurons during development and in adult neurogenic niches.
• Key negative regulators include PTEN, which restrains dopaminergic differentiation through ERK-dependent inhibition of S6K signaling in human neural stem cells.
• Zeb2 acts as a negative regulator of midbrain dopaminergic axon growth and target innervation, indirectly influencing differentiation outcomes.
• Caveolin-1 downregulation promotes dopaminergic neuron-like differentiation of human adipose-derived mesenchymal stem cells, highlighting its role as a negative regulator.
• Dysregulation of this process is implicated in Parkinson's disease, where loss of dopaminergic neurons is a hallmark, and in neurodevelopmental disorders.
Description
The Gene Ontology (GO) term GO:1904339, negative regulation of dopaminergic neuron differentiation, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of dopaminergic neuron differentiation. Dopaminergic neurons are critical for motor control, reward, and cognition, and their differentiation is tightly controlled by a network of intrinsic and extrinsic signals. Understanding the negative regulation of this process is fundamental for developmental neurobiology and for regenerative medicine approaches aimed at generating dopaminergic neurons for cell replacement therapies. Perturbations in the signaling pathways that restrain dopaminergic differentiation can lead to excessive or insufficient neuron production, contributing to neurodevelopmental and neurodegenerative disorders. This article synthesizes current knowledge on the mechanisms, key genes, and experimental models used to study GO:1904339, providing a resource for researchers investigating dopaminergic neuron biology and disease.
negative regulation of dopaminergic neuron differentiation At A Glance
| GO ID | GO:1904339 |
|---|---|
| GO term | negative regulation of dopaminergic neuron differentiation |
| Ontology | biological_process |
| Synonym | down regulation of dopaminergic neuron differentiation, down-regulation of dopaminergic neuron differentiation, downregulation of dopaminergic neuron differentiation, inhibition of dopaminergic neuron differentiation |
| Major function | Stops, prevents or reduces the frequency, rate or extent of dopaminergic neuron differentiation |
| Related processes | Regulation of neurogenesis, dopaminergic neuron differentiation, axon growth, target innervation |
| Key negative regulators | PTEN, Caveolin-1, Zeb2, LRRK2 (context-dependent), interferon-γ signaling |
| Disease relevance | Parkinson's disease, neurodevelopmental disorders, potential implications in cancer and stem cell therapy |
What Is GO:1904339?
In our own words, GO:1904339 encompasses any cellular or molecular event that inhibits, delays, or reduces the generation of dopaminergic neurons from progenitor or stem cells. This includes signaling cascades that block the expression or activity of pro-differentiation factors, as well as mechanisms that maintain progenitors in an undifferentiated state or promote alternative fates. The term is a biological process and is synonymous with down regulation, down-regulation, downregulation, or inhibition of dopaminergic neuron differentiation.
Why Is negative regulation of dopaminergic neuron differentiation Important in Cell Biology?
Negative regulation of dopaminergic neuron differentiation is crucial for maintaining the correct number and spatial distribution of dopaminergic neurons during development and in adult neurogenesis. Imbalances in this process can lead to a loss of dopaminergic neurons, as seen in Parkinson's disease, or to aberrant neurogenesis that may contribute to other neurological disorders. Moreover, understanding how to manipulate this negative regulation is key for optimizing stem cell-based therapies, where controlled differentiation into dopaminergic neurons is desired. Signaling pathways such as PTEN/ERK/S6K and Caveolin-1 provide potential targets for modulating dopaminergic differentiation in vitro and in vivo.
• Maintains proper dopaminergic neuron numbers during midbrain development.
• Prevents premature or excessive differentiation that could deplete progenitor pools.
• Its dysregulation is linked to Parkinson's disease pathogenesis.
• Influences axon growth and target innervation of midbrain dopaminergic neurons via Zeb2.
• Modulates the efficiency of stem cell differentiation protocols for cell therapy.
• Interferon-γ signaling synergizes with LRRK2 to affect neuronal survival and differentiation.
• PTEN acts as a negative regulator through ERK-dependent inhibition of S6K in human neural stem cells.
• Caveolin-1 downregulation enhances dopaminergic neuron-like differentiation of adipose-derived mesenchymal stem cells.
• Cholinergic and dopaminergic differentiation of mesenchymal stem cells can be influenced by negative regulators.
• GDNF delivery in Parkinson's disease models highlights the therapeutic potential of modulating dopaminergic neuron survival and differentiation.
What Happens During negative regulation of dopaminergic neuron differentiation?
Initiation of negative regulatory signals
In simple terms: Certain molecules tell the cell to stop making dopaminergic neurons.
Negative regulation begins when extracellular or intracellular signals activate pathways that oppose dopaminergic differentiation. For example, PTEN activation leads to ERK-dependent inhibition of S6K signaling, which restrains dopaminergic neuronal differentiation in human neural stem cells. Similarly, interferon-γ signaling can synergize with LRRK2 to modulate neuronal differentiation and survival, potentially acting as a negative regulator in certain contexts.
Transcriptional and post-transcriptional control
In simple terms: The cell changes which genes are turned on or off to block neuron formation.
Negative regulators can act by altering the expression of pro-differentiation genes. Zeb2 is a transcription factor that negatively regulates midbrain dopaminergic axon growth and target innervation, indirectly affecting differentiation outcomes. Caveolin-1 downregulation promotes dopaminergic neuron-like differentiation, indicating that its presence normally suppresses this process. These factors may repress key dopaminergic genes such as TH, DAT, and Nurr1, though specific mechanisms require further study.
Modulation of progenitor proliferation and survival
In simple terms: The cell decides to keep dividing instead of becoming a neuron.
Negative regulation often involves maintaining progenitors in a proliferative state or promoting their survival without differentiation. PTEN, a tumor suppressor, negatively regulates the PI3K/Akt pathway, and its activity can inhibit S6K, thereby blocking differentiation. This ensures that neural stem cells do not prematurely differentiate, preserving the progenitor pool.
Integration with extrinsic cues
In simple terms: Outside signals from the environment also tell cells not to become dopaminergic neurons.
Extrinsic factors such as inflammatory cytokines (e.g., interferon-γ) can influence dopaminergic differentiation. Interferon-γ signaling synergizes with LRRK2 in human iPSC-derived neurons and microglia, affecting neuronal survival and potentially differentiation. Additionally, GDNF delivery in Parkinson's disease models primarily supports survival, but its absence may shift the balance toward negative regulation.
Outcome: reduced dopaminergic neuron differentiation
In simple terms: The final result is fewer dopaminergic neurons being made.
The culmination of these negative regulatory mechanisms is a decrease in the number of newly generated dopaminergic neurons. This can be measured by reduced expression of dopaminergic markers and decreased functional dopaminergic neuron counts. Such control is vital for normal brain development and for preventing exhaustion of neural stem cell pools.
Key Genes Involved in GO:1904339 negative regulation of dopaminergic neuron differentiation
The following genes and proteins have been experimentally implicated in the negative regulation of dopaminergic neuron differentiation or closely related processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTEN | Lipid phosphatase that negatively regulates PI3K/Akt signaling; inhibits S6K via ERK to block dopaminergic differentiation | Studied in human neural stem cells; knockout enhances dopaminergic differentiation |
| CAV1 | Caveolin-1; its downregulation promotes dopaminergic neuron-like differentiation | Investigated in human adipose-derived mesenchymal stem cells |
| ZEB2 | Transcription factor that negatively regulates midbrain dopaminergic axon growth and target innervation | Studied in mouse models; affects differentiation indirectly |
| LRRK2 | Kinase implicated in Parkinson's disease; interacts with interferon-γ signaling to modulate neuronal survival | Used in human iPSC-derived neurons and microglia |
| IFNG | Interferon-γ; cytokine that synergizes with LRRK2 to affect neurons and microglia | Studied in human iPSC models |
| GDNF | Glial cell line-derived neurotrophic factor; supports survival of dopaminergic neurons | Delivered in Parkinson's disease trials; may influence differentiation |
| TH | Tyrosine hydroxylase; rate-limiting enzyme in dopamine synthesis; marker of dopaminergic neurons | Used to assess differentiation efficiency |
| DAT (SLC6A3) | Dopamine transporter; marker of mature dopaminergic neurons | Measured to evaluate differentiation |
| NURR1 (NR4A2) | Transcription factor essential for dopaminergic neuron development | Its expression is modulated during differentiation |
| PITX3 | Homeodomain transcription factor critical for midbrain dopaminergic neuron maintenance | Marker of differentiated dopaminergic neurons |
| LMX1A | Transcription factor required for midbrain dopaminergic progenitor specification | Used to assess differentiation status |
| FOXA2 | Forkhead box protein A2; involved in midbrain dopaminergic neuron development | Marker of dopaminergic progenitors |
| SHH | Sonic hedgehog; morphogen that promotes dopaminergic differentiation | Its inhibition may contribute to negative regulation |
| FGF8 | Fibroblast growth factor 8; involved in midbrain patterning | Modulates dopaminergic differentiation |
| WNT1 | Wingless-type MMTV integration site family member 1; can influence dopaminergic neurogenesis | Context-dependent roles in differentiation |
| S6K (RPS6KB1) | Ribosomal protein S6 kinase; downstream of mTOR; inhibited by PTEN-ERK signaling to block differentiation | Studied in human neural stem cells |
| ERK (MAPK1/3) | Extracellular signal-regulated kinases; mediate PTEN effects on S6K | Key signaling node in negative regulation |
| CDKN1B (p27Kip1) | Cyclin-dependent kinase inhibitor; can promote cell cycle exit and differentiation | Potential negative regulator of progenitor proliferation |
How Is negative regulation of dopaminergic neuron differentiation Regulated?
The negative regulation of dopaminergic neuron differentiation is itself controlled by multiple signaling pathways. PTEN acts as a central negative regulator by inhibiting PI3K/Akt signaling and, through ERK, inhibiting S6K, which blocks differentiation. Caveolin-1 downregulation relieves inhibition, promoting differentiation. Interferon-γ signaling, in synergy with LRRK2, can modulate neuronal survival and differentiation, potentially acting as a negative regulator in certain contexts. Additionally, transcription factors such as Zeb2 negatively regulate axon growth and innervation, indirectly affecting differentiation. The balance between pro- and anti-differentiation signals determines the final number of dopaminergic neurons.
negative regulation of dopaminergic neuron differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTEN | Parkinson's disease, cancer, stem cell differentiation | PTEN knockout human neural stem cells; differentiation assays |
| LRRK2 | Parkinson's disease | LRRK2 mutant human iPSC-derived neurons and microglia |
| CAV1 | Dopaminergic differentiation efficiency | Caveolin-1 knockdown in human adipose-derived mesenchymal stem cells |
| ZEB2 | Midbrain dopaminergic axon growth and innervation | Zeb2 knockout mouse models |
| GDNF | Parkinson's disease | GDNF delivery in animal models and clinical trials |
Parkinson's disease
Parkinson's disease is characterized by the progressive loss of midbrain dopaminergic neurons. Negative regulation of dopaminergic neuron differentiation may contribute to the failure of endogenous repair mechanisms or to the reduced generation of new neurons in the adult brain. GDNF delivery has been explored as a therapy to support surviving dopaminergic neurons, but its effects on differentiation are complex. LRRK2 mutations, common in Parkinson's disease, interact with interferon-γ signaling to influence neuronal survival and differentiation, highlighting the role of negative regulatory pathways in disease pathogenesis.
Neurodevelopmental disorders
Disruptions in the negative regulation of dopaminergic neuron differentiation can lead to altered numbers of dopaminergic neurons during development, potentially contributing to neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and schizophrenia, though direct evidence is still emerging. Proper control of differentiation is essential for normal brain wiring and function.
Cancer and stem cell biology
PTEN, a key negative regulator of dopaminergic differentiation, is a well-known tumor suppressor. Its role in inhibiting differentiation through S6K signaling intersects with cancer pathways, as uncontrolled proliferation and blocked differentiation are hallmarks of cancer. Understanding how PTEN and similar factors regulate dopaminergic differentiation may provide insights into stem cell quiescence and tumorigenesis.
From negative regulation of dopaminergic neuron differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PTEN negatively regulate dopaminergic differentiation via ERK-S6K? | PTEN knockout human neural stem cells; pharmacological inhibition of ERK or S6K |
| Does Caveolin-1 downregulation promote dopaminergic differentiation? | Caveolin-1 knockdown in human adipose-derived mesenchymal stem cells |
| How does LRRK2 mutation affect interferon-γ signaling in dopaminergic neurons? | LRRK2 mutant human iPSC-derived neurons and microglia |
| What is the role of Zeb2 in midbrain dopaminergic axon growth? | Zeb2 conditional knockout mice |
| Can GDNF delivery enhance dopaminergic neuron survival in Parkinson's disease? | GDNF infusion in rodent and primate models; clinical trials |
| What transcription factors control dopaminergic differentiation? | Overexpression or knockout of NURR1, PITX3, LMX1A in stem cells |
How to Study the negative regulation of dopaminergic neuron differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on differentiation | Identify negative regulators of dopaminergic differentiation |
| RNA-seq | Transcriptional changes | Compare gene expression in PTEN KO vs. wild-type neural stem cells |
| Phosphoproteomics | Phosphorylation events | Map ERK-S6K signaling during differentiation |
| Immunofluorescence | Protein expression and localization | Quantify TH+ dopaminergic neurons |
| Live-cell imaging | Axon growth and innervation | Study Zeb2 role in midbrain dopaminergic neurons |
| Electrophysiology | Functional maturation | Assess action potentials in derived dopaminergic neurons |
| Single-cell RNA-seq | Cell heterogeneity | Profile differentiation cultures |
| GDNF delivery assays | Neuronal survival and function | Evaluate therapeutic potential in Parkinson's models |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify negative regulators of dopaminergic neuron differentiation. By differentiating human pluripotent stem cells into dopaminergic neurons and selecting for cells that differentiate more efficiently, researchers can uncover genes whose loss enhances differentiation. PTEN and Caveolin-1 are examples of such negative regulators identified through candidate approaches.
Transcriptomics and epigenomics
RNA-seq and ATAC-seq can reveal changes in gene expression and chromatin accessibility during dopaminergic differentiation. Comparing cells with and without negative regulators (e.g., PTEN knockout) can identify downstream targets and pathways. Single-cell RNA-seq allows profiling of heterogeneous differentiation cultures to pinpoint cell states.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation during differentiation. For example, PTEN-ERK-S6K signaling involves phosphorylation events that can be monitored by phosphoproteomics. This approach helps elucidate the molecular mechanisms of negative regulation.
Imaging and functional assays
Immunofluorescence for dopaminergic markers (TH, DAT, NURR1) and high-content imaging can quantify differentiation efficiency. Live-cell imaging can track axon growth and innervation in Zeb2 models. Electrophysiology can assess functional maturation of derived dopaminergic neurons.
How CRISPR Can Be Used to Study GO:1904339 negative regulation of dopaminergic neuron differentiation
Knockout
CRISPR knockout of negative regulators such as PTEN or CAV1 can enhance dopaminergic neuron differentiation. For example, PTEN knockout in human neural stem cells increases dopaminergic differentiation through ERK-dependent inhibition of S6K. Caveolin-1 knockout promotes dopaminergic neuron-like differentiation of adipose-derived mesenchymal stem cells. These models are valuable for studying the loss-of-function effects of negative regulators.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants, such as LRRK2 G2019S, which affects neuronal survival and differentiation in human iPSC-derived neurons. Such models help dissect the precise contribution of specific mutations to negative regulation of dopaminergic differentiation.
Knock-in
Knock-in of reporter genes (e.g., TH-GFP) or tags allows real-time monitoring of dopaminergic differentiation. Knock-in of disease-relevant mutations, such as LRRK2 G2019S, into iPSCs provides isogenic models to study negative regulation in a patient-relevant context. These models are essential for drug discovery and mechanistic studies.
Overexpression
Overexpression of negative regulators like PTEN or Caveolin-1 can suppress dopaminergic differentiation, providing gain-of-function models. For instance, overexpression of PTEN in neural stem cells inhibits differentiation via S6K. Conversely, overexpression of pro-differentiation factors can overcome negative regulation. These models help validate the sufficiency of candidate genes in blocking differentiation.
How EDITGENE Supports negative regulation of dopaminergic neuron differentiation Research
Researchers studying negative regulation of dopaminergic neuron differentiation-related genes often need to determine whether a candidate gene is causally involved in restraining or promoting this process. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutant, knock-in, and overexpression cell models, enabling precise functional interrogation of these regulatory pathways.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of dopaminergic neuron differentiation research.
Frequently Asked Questions About negative regulation of dopaminergic neuron differentiation
What is GO:1904339?
GO:1904339 is a Gene Ontology term for negative regulation of dopaminergic neuron differentiation, describing any process that stops, prevents, or reduces the frequency, rate, or extent of dopaminergic neuron differentiation.
What genes are involved in negative regulation of dopaminergic neuron differentiation?
Key genes include PTEN, CAV1, ZEB2, LRRK2, and IFNG, among others, which have been experimentally implicated in restraining this process.
How does PTEN negatively regulate dopaminergic neuron differentiation?
PTEN inhibits PI3K/Akt signaling and, through ERK, inhibits S6K, thereby blocking dopaminergic differentiation in human neural stem cells.
What is the role of Caveolin-1 in dopaminergic differentiation?
Caveolin-1 acts as a negative regulator; its downregulation promotes dopaminergic neuron-like differentiation of human adipose-derived mesenchymal stem cells.
How is Zeb2 involved in dopaminergic neuron differentiation?
Zeb2 is a transcription factor that negatively regulates midbrain dopaminergic axon growth and target innervation, indirectly affecting differentiation.
What diseases are associated with dysregulation of this process?
Parkinson's disease and neurodevelopmental disorders are linked to altered negative regulation of dopaminergic neuron differentiation.
What experimental models are used to study GO:1904339?
Models include PTEN knockout human neural stem cells, Caveolin-1 knockdown mesenchymal stem cells, LRRK2 mutant iPSC-derived neurons, and Zeb2 knockout mice.
How can CRISPR be used to study negative regulation of dopaminergic neuron differentiation?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to manipulate candidate genes and assess their effects on differentiation.
What signaling pathways control negative regulation of dopaminergic neuron differentiation?
The PTEN/ERK/S6K pathway, Caveolin-1, interferon-γ signaling, and LRRK2 are key regulators.
Why is negative regulation of dopaminergic neuron differentiation important for Parkinson's disease?
Loss of dopaminergic neurons is a hallmark of Parkinson's disease; understanding negative regulation may reveal strategies to promote neuronal survival or regeneration.
Conclusion
GO:1904339, negative regulation of dopaminergic neuron differentiation, is a critical biological process that ensures proper numbers of dopaminergic neurons are generated during development and in adult neurogenesis. Key negative regulators such as PTEN, Caveolin-1, and Zeb2 have been identified, and their dysregulation is linked to Parkinson's disease and other neurological disorders. Advances in CRISPR-based models and multi-omics approaches are accelerating our understanding of these pathways, offering new opportunities for therapeutic intervention and stem cell engineering.
References
- 1. Srivastava AK et al.. 2016. Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.. Hum Genomics 10 Suppl 1(Suppl 1):12 PMID: 27294413
- 2. Han C et al.. 2021. Caveolin-1 downregulation promotes the dopaminergic neuron-like differentiation of human adipose-derived mesenchymal stem cells.. Neural Regen Res 16(4):714-720 PMID: 33063733
- 3. Panagiotakopoulou V et al.. 2020. Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells.. Nat Commun 11(1):5163 PMID: 33057020
- 4. Hegarty SV et al.. 2017. Zeb2 is a negative regulator of midbrain dopaminergic axon growth and target innervation.. Sci Rep 7(1):8568 PMID: 28819210
- 5. Lee JE et al.. 2016. PTEN Promotes Dopaminergic Neuronal Differentiation Through Regulation of ERK-Dependent Inhibition of S6K Signaling in Human Neural Stem Cells.. Stem Cells Transl Med 5(10):1319-1329 PMID: 27388240
- 6. Marei HES et al.. 2018. Cholinergic and dopaminergic neuronal differentiation of human adipose tissue derived mesenchymal stem cells.. J Cell Physiol 233(2):936-945 PMID: 28369825
- 7. Patel NK et al.. 2007. GDNF delivery for Parkinson's disease.. Acta Neurochir Suppl 97(Pt 2):135-54 PMID: 17691299
- 8. Respondek M et al.. 2015. [Regulation of neurogenesis: factors affecting of new neurons formation in adult mammals brain].. Postepy Hig Med Dosw (Online) 69:1451-61 PMID: 27259217
